We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Two Genes Predict Survival in Early Lung Cancer

By HospiMedica staff writers
Posted on 08 Mar 2007
Among patients with early-stage non–small-cell lung cancer (NSCLC) undergoing potentially curative surgery, the coexpression of 2 gene proteins identifies a subgroup with an excellent prognosis.

Investigators from the Lee Moffitt Cancer Center (Tampa, FL, USA) reported in the February 22, 2007, issue of the New England Journal of Medicine that the two genes, both involved in DNA synthesis and repair, are the regulatory subunit of ribonucleotide reductase (RRM1) and the excision repair cross-complementation group 1 (ERCC1). More...
About 30% of the patients investigated (55 of 184) had high levels of both gene markers, and clinical records showed that they had excellent outcomes.

Patients who have high expression of these two gene proteins do not need to receive adjuvant chemotherapy, as almost all of these patients are truly cured by surgery, said senior author Gerold Bepler, M.D., Ph.D.

Adjuvant chemotherapy is given to most patients with completely resected lung cancer, usually immediately after surgery, Dr. Bepler explained. The aim is to prevent disease recurrence, which occurs in about half the patients. However, this treatment has resulted in an approximately 10% improvement in patients' survival, meaning that many patients get chemotherapy after surgery without getting a benefit, and some will even be harmed by this.

For their study, Dr. Bepler and colleagues developed a process for automative quantitative determination of the RRM1 protein in routinely processed histologic specimens. They also measured expression of ERCC1 and another protein, the phosphatase and tensin homolog (PTEN), but found that this third marker was not correlated with survival.

The researchers commented that analysis of RRM1 has been technically difficult in the past, but the system they developed allows gene-expression analysis of both RRM1 and ERCC1 that is objective, reliable, and reproducible.

The same 2 gene markers have previously been shown to predict which patients with advanced NSCLC have a poor response to chemotherapy with gemcitabine and platinum compounds.

RRM1 and ERCC1 are important in controlling the 'integrity' of the DNA during cell doubling, Dr. Bepler explained. We already know that chemo does not work well in patients with high expression of both genes, because chemo works by causing DNA damage, which is fixed by these genes. Hence, patients with low levels of these genes have a more aggressive cancer and benefit most from chemotherapy, he said.


Related Links:
Lee Moffitt Cancer Center

Gold Member
Neonatal Heel Incision Device
Tenderfoot
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Hybrid Arch Device
Neo EDE
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Critical Care

view channel
Image Credit: Adobe Stock

New ECG Foundation Model Enables Broad Cardiac Diagnosis and Risk Prediction

Electrocardiograms are central to cardiovascular decision-making, but conventional artificial intelligence models are often trained for narrow tasks, such as detecting a single arrhythmia.... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.